Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Precision BioSciences ( (DTIL) ) is now available.
On March 17, 2026, Precision BioSciences hosted a live investor and key opinion leader webcast to provide an update on its PBGENE-DMD gene-editing program and the FUNCTION-DMD Phase 1/2 trial for Duchenne muscular dystrophy. Pediatric neurologist Aravindhan Veerapandiyan and patient advocate Pat Furlong joined company management to discuss the unmet need, current DMD treatment landscape, and the planned clinical strategy, positioning PBGENE-DMD as a potentially differentiated approach aimed at restoring muscle function and informing investors about near-term development milestones across the DMD franchise.
The most recent analyst rating on (DTIL) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Precision BioSciences stock, see the DTIL Stock Forecast page.
Spark’s Take on DTIL Stock
According to Spark, TipRanks’ AI Analyst, DTIL is a Neutral.
The score is held back primarily by weak financial performance—sharp TTM revenue decline, a return to large losses, and substantial ongoing cash burn. Offsetting this, technicals show strong upside momentum (price above key moving averages, positive MACD), and a positive corporate update highlights progress and a stated cash runway; valuation remains difficult to assess due to a negative P/E and no dividend yield provided.
To see Spark’s full report on DTIL stock, click here.
More about Precision BioSciences
Precision BioSciences, Inc. is a biotechnology company focused on developing genome-editing therapies based on its proprietary ARCUS technology platform. Its pipeline includes programs such as PBGENE-DMD for Duchenne muscular dystrophy and PBGENE-HBV for chronic hepatitis B, targeting severe genetic and infectious diseases with high unmet medical need.
Average Trading Volume: 246,681
Technical Sentiment Signal: Buy
Current Market Cap: $155.8M
See more insights into DTIL stock on TipRanks’ Stock Analysis page.